During this webinar, Ken Getz of Tufts CSDD and Patrick Hughes of CluePoints discuss new research findings. Learn all about recent Tufts CSDD insights into the adoption of RBQM and its associated challenges, the shift to new clinical trial execution models, and ICH E6 (R3) regulatory guidance updates.